Candel therapeutics reports encouraging initial survival data from phase 2 clinical trial of can-2409 in non-small cell lung cancer

Needham, mass., sept. 26, 2023 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced updated activity data from its ongoing, open-label, phase 2 clinical trial of can-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ici) treatment in patients with non-resectable, stage iii/iv non-small cell lung cancer (nsclc), who have an inadequate response to front line anti-pd(l)1 therapy. these patients historically have had an expected median overall survival of 10-13 months (reckamp k et al. j clin onc 2022;40:2295-2306). the aim of the can-2409 immunotherapy antitumor strategy is to raise the tail on the survival curve by increasing the number of long survivors beyond 10-13 months.
CADL Ratings Summary
CADL Quant Ranking